RESUMO
BACKGROUND: Fibroblast growth factor 23 (FGF23), an important regulator of phosphate and vitamin D metabolism, has also been suggested to perform metabolic functions. This retrospective study evaluated the relationship between metabolic syndrome (MetS) and fasting FGF23 levels in patients undergoing kidney transplantation (KT). METHODS: Serum carboxyl-terminal FGF23 levels were measured in fasting blood samples of 74 KT patients using a commercially available enzyme-linked immunosorbent assay. MetS and its components were defined using the diagnostic criteria of the International Diabetes Federation. RESULTS: Twenty-four KT patients (32.4%) had MetS. Hypertension (P = .008); diabetes (P = .002), body weight (P < .001); body mass index (P < .001); waist circumference (P < .004); body fat mass (P < .001); systolic blood pressure (P = .008); and levels of triglycerides (P = .003), blood urea nitrogen (P = .007), and insulin (P = .004); homeostasis model assessment of insulin resistance (P = .001); and FGF23 (P = .002) were higher, whereas high-density lipoprotein cholesterol (P = .049) levels were lower in KT patients with MetS. Multivariable logistic regression analysis including significant variables revealed that FGF23 (odds ratio 1.030, 95% confidence interval [CI] 1.000-1.060, P = .048) was an independent predictor of MetS in KT patients. The area under the receiver operating characteristic curve to evaluate the ability of serum FGF23 in discriminating KT patients with MetS was 0.727 (95% CI 0.611-0.824, P = .0005). CONCLUSION: These results revealed that a high serum FGF23 level was positively associated with MetS in KT patients.
